PROCLEIX® Assays
The PROCLEIX® WNV Assay and the PROCLEIX® HIV-1/HCV Assay provide blood centers with a powerful combination for blood screening with unique nucleic acid amplification technology. The PROCLEIX® ULTRIO® Assay is designed to detect HIV-1, HCV and HBV simultaneously in a single tube.
Not available for use and sale in all countries.
Learn more by visiting the approval page
The PROCLEIX® WNV Assay is the first Nucleic Acid Testing solution approved by the FDA for qualitative detection of the West Nile virus in RNA plasma specimens from individual donors of blood, organs, cells and tissues.
Not available for use and sale in all countries.
Learn more by visiting the approval page
The PROCLEIX® HIV-1/HCV Assay detects both viruses in a single tube, thanks to transcription-mediated amplification (TMA) technology. It was the first NAT solution to be approved for blood screening in the US and to receive the CE Mark in Europe.
Not available for use and sale in all countries.
Learn more by visiting the approval page
The PROCLEIX® ULTRIO® Assay is designed to combine the early detection capabilities of NAT with single tube TMA technology to deliver simultaneous results for HIV-1, HCV and HBV.
PROCLEIX is a trademark of Novartis Vaccines and Diagnostics, Inc.
About Novartis Vaccines
Novartis Vaccines is a leader in providing products to fight more than 20 vaccine-preventable viral and bacterial diseases. Novartis Vaccines is the division researching novel treatments.